The Efficacy and Safety of Peginterferon-alpha-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting
- Authors
- Kwon, Jung Hyun; Kim, Young Seok; Kim, Sang Gyune; Jang, Jeong Won; Kim, Tae Hun; Jung, Young Kul; Kwon, Oh Sang
- Issue Date
- 15-Mar-2013
- Publisher
- 거트앤리버 발행위원회
- Keywords
- Peginterferon; Chronic hepatitis B; Asian continental ancestry group
- Citation
- Gut and Liver, v.7, no.2, pp 197 - 205
- Pages
- 9
- Journal Title
- Gut and Liver
- Volume
- 7
- Number
- 2
- Start Page
- 197
- End Page
- 205
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13825
- DOI
- 10.5009/gnl.2013.7.2.197
- ISSN
- 1976-2283
2005-1212
- Abstract
- Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon alpha-2a therapy. The efficacy of and compliance to peginterferon a-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon alpha-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1 +/- 15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both III3V DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/niL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2x10(6) IU/mL. Conclusions: Peginterferon alpha-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies. (Gut Liver 2013;7:197-205)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13825)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.